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Factor VIII/von Willebrand Factor 
(FVIII/vWF) complex, a molecule involved in 
coagulation, can be physically associated with 
osteoprotegerin (OPG). OPG is an anti-
osteoclastic protein and a soluble receptor for 
the pro-apoptotic protein TRAIL, suggesting 
a potential role of FVIII/vWF complex in 
bone and cancer biology. We thus assessed the 
effects of FVIII/vWF complex on 
osteoclastogenesis and cell survival. We first 
evidenced that FVIII/vWF complex inhibited 
RANKL-induced osteoclastogenesis, and 
enhanced the inhibitory effect of OPG. 
Interestingly, we revealed by surface plasmon 
resonance that FVIII/vWF complex bound to 
RANKL, whereas recombinant FVIII and 
vWF did not. By modeling, we showed that 
the OPG-binding domain to the A1-domain of 
vWF was closely located and partially 
overlapped to its binding site to RANKL. 
Then, we demonstrated that FVIII/vWF 
complex cancelled the inhibitory activity of 
OPG on TRAIL-induced apoptosis, and 
characterized interactions between these 
molecules. The present work evidenced a 
direct activity of FVIII/vWF complex on 
osteoclasts and on induced cell apoptosis, 
pointing out its potential involvement in 
physiological bone remodeling or in bone 
damages associated with severe hemophilia 
and cancer development.  
 
The molecular triad OPG/RANK/RANKL 
is a crucial parameter of bone biology. Receptor 
Activator of Nuclear factor κB Ligand, 
(RANKL), a member of the Tumor Necrosis 
Factor (TNF) family, is mainly expressed by 
osteoblasts in the bone microenvironment and 
acts as a pro-resorption factor (1,2); RANKL 
binds to its receptor RANK expressed at the cell 
surface of osteoclast precursors and induces 
osteoclastic differentiation and maturation, 
leading to bone resorption (3,4). Osteoprotegerin 
(OPG), also mainly produced by osteoblasts, is a 
soluble decoy receptor for RANKL preventing 
the binding of RANKL to RANK, and thus 
inhibiting osteoclastogenesis (5-7). Bone 
turnover is tightly controlled by the 
OPG/RANK/RANKL triad, and any change in 
the balance OPG/RANKL leads to pathological 
conditions (7). OPG is also a receptor for Tumor 
Necrosis factor-Related Apoptosis-Inducing 
Ligand, TRAIL (8,9), a cytokine which is able to 
induce a rapid cancer cell death by apoptosis (9-
11). Interestingly, the binding of OPG to TRAIL 
completely inhibits TRAIL-induced cytotoxicity 
(8). OPG possess anti-apoptotic properties and 
therefore could be considered as a pro-tumoral 
agent. 
Factor VIII is a plasma glycoprotein, 
mainly synthesized by hepatocytes, but also by 
kidney, sinusoidal endothelial cells, and in small 
amounts by lymphatic tissues (12). Factor VIII is 
one of the main coagulation factors and allows 
the completion of the coagulation process. Factor 
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VIII circulates in plasma in a non-covalent 
complex with the von Willebrand factor 
(FVIII/vWF complex). The most well known-
genetic disease associated with Factor VIII is 
hemophilia A, which shows an X-linked 
inheritance (13). A second important disease 
associated with low Factor VIII levels is von 
Willebrand disease (vWD), a bleeding disorder 
(14,15). Patients suffering from vWD have 
primary hemostasis defects leading to 
mucocutaneous bleeding or spontaneous deep 
tissue bleeding, such as in hemophilia A, or both 
(14). Bleeding diseases could be associated with 
different bone phenotypes. For instance, in a 
murine model of platelet-type vWD, a significant 
increase of bone mass and cortical tickness due 
to a reduction of the number of osteoclasts is 
observed (16). In contrast, various case reports 
suggest that children suffering from severe 
hemophilia have more risks to have low bone 
density and osteopenia/osteoporosis, 
preferentially caused by physical inactivity and 
leading to loss of joint function, shorter height, 
lower weight and muscle atrophy (17,18) 
Von Willebrand factor is a multimeric 
protein containing many binding domains for 
various proteins such as the D’-D3 domain 
which binds FVIII (19) and the A1 domain 
which can bind different proteins such as the 
platelet glycoprotein Ib (20), heparin (21) and 
snake venom toxins (bitiscetin (22) and 
botrocetin (23)). Recently, it has been shown that 
the vWF is physically complexed to OPG 
(through the A1-domain) within the Weibel-
Palade bodies and also in plasma, revealing a 
possible modulatory role of OPG in hemostasis 
(24,25). The aim of the present study was to 
characterize the effects of FVIII/vWF complex 
on osteoclastogenesis and cancer cell survival, 
and then interactions between complex 
FVIII/vWF complex and three members of TNF 
cytokine / cytokine receptor family: OPG, 
RANKL and TRAIL. The data obtained 
demonstrated that FVIII/vWF complex binds to 
OPG and RANKL, and thus indirectly 
participates to bone biology. Indeed, we first 
demonstrated that FVIII/vWF complex inhibits 
RANKL-induced osteoclastogenesis. Secondly, 
we demonstrated that the FVIII/vWF complex 
abolished the inhibitory effect of OPG on 
TRAIL-induced apoptosis, revealing a key role 
of FVIII/vWF complex in cancer development.  
 
EXPERIMENTAL PROCEDURES 
Osteoclast differentiation assay- Generation of 
osteoclasts from murine RAW 264.7 cells was 
performed as previously described (26) in the 
presence of recombinant human RANKL (100 
ng/ml) (kindly provided by Amgen Inc, USA), 
human OPG (100 ng/ml) (R&D systems, UK), 
FVIII/vWF complex purified from plasma 
(ProSpec, Israel) or recombinant FVIII (Octocog 
alpha kindly provided by CSL Behring, USA) (1 
or 2 U/ml). Generation of osteoclasts from 
human CD14+ monocytes was described 
previously (26). Briefly, purified CD14+ cells 
were cultured in α-MEM with 10% FCS and 25 
ng/ml human M-CSF (R&D systems). After 3 
days of culture, 100 ng/ml RANKL, 100 ng/ml 
OPG, and 1 U/ml FVIII or FVIII/vWF were 
added. Multinucleated cells formed with 3 nuclei 
and more were counted after TRAP staining 
(Sigma, France). 
 
Cell proliferation- Human osteosarcoma cell 
lines MG63 and SaOS2 as well as the Ewing’s 
sarcoma cell line TC71 were cultured in DMEM 
containing 10 % FCS. MG63 and SaOS2 cells 
were seeded at 500 cells/well in 96-well plates, 
and TC71 at 1500 cells/well. Cells were treated 
with 50-100 ng/ml TRAIL (R&D systems), 50-
100 ng/ml OPG and 1 U/ml of FVIII/vWF 
complex for 72 hours. After the culture period, 
cell viability was determined by XTT assay 
(Roche Molecular Biomedicals, Germany). 
 
Hoechst staining and caspase-3 activity- Cell 
death was monitored microscopically after 
Hoechst 33258 (Sigma) staining. MG63, SaOS2 
and TC71 cells were seeded in a 96-multiwell 
plate and treated or not with TRAIL (50 ng/ml), 
OPG (50 ng/ml) and FVIII/vWF complex (1 
U/ml) for 16 h, stained with 10 µg/ml Hoechst 
reagent for 20 min at 37°C, and then observed 
under UV microscopy (DMRXA; Leica, 
Germany). Caspase-3 activity was assessed on 
10 µl of total treated cell lysates using the kit 
CaspACE assay system, fluorometric (Promega, 
USA) following the manufacturer’s 
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recommendations. Results are expressed in 
arbitrary units and corrected for protein content. 
 
Surface plasmon resonance-binding assays-
Experiments were carried out on a BIAcore 3000 
instrument (Biacore, Sweden). OPG (1 µg/mL in 
5 mM maleate, pH 6.0), RANKL (2 µg/mL in 5 
mM maleate, pH 5.75) and TRAIL (10 µg/mL in 
10 mM acetate, pH 5.5) were covalently 
immobilized to the dextran matrix of a CM5 
sensor chip (BIAcore) at a flow rate of 5 µl/min. 
Immobilization levels ranging of 300 RU for 
OPG, 400 RU for RANKL and 700 RU for 
TRAIL were obtained. vWF (Haematologic 
Technologies, USA) was immobilized on a C1 
sensorchip at 2000 RU. Binding assays were 
performed at 25°C in 10 mM Hepes buffer, pH 
7.4, containing 0.15 M NaCl and 0.005% P20 
surfactant (HBS-P buffer, BIAcore) or in a pH 
6.5 buffer containing 20 mM Bis-Tris and 10 
mM CaCl2, at a flow rate of 30 µl/min for 
immobilized-OPG, and 20 µl/min for 
immobilized-RANKL and immobilized-TRAIL. 
Kds of OPG for vWF and FVIII/vWF were 
determined using single cycle kinetics, starting 
with 25 nM of OPG or with 300 nM of 
FVIII/vWF, then ½ dilutions. For binding 
analysis over the immobilized-RANKL or 
immobilized-TRAIL chip, binding of OPG alone 
or preincubated for 120 min with different 
concentrations of FVIII/vWF complex was 
performed for 4 min at a flow rate of 20 µl/min, 
followed by dissociation for 2.5 min. The 
resulting sensorgrams were fitted using BiaEval 
4.1 software (Biacore). For Kd calculations, the 
following molecular weights were used: 
recombinant FVIII: 330 kDa and FVIII/vWF 
complex: 540 kDa. 
 
ELISA assay- FVIII/vWF complex was coated at 
1 U/ml on a 96-well plate overnight at room 
temperature (RT). OPG or RANKL (both were 
tested at 500, 100 and 10 ng/ml) were incubated 
for 2 hours at RT. After 2 washes with 
PBS/Tween 0.05%, the revelation of the binding 
of OPG or RANKL to FVIII/vWF complex was 
performed using a specific biotinylated antibody 
against each molecule (anti-OPG was from R&D 
systems and anti-RANKL from Peprotech, 
USA). Streptavidin conjugated to horseradish 
peroxydase (R&D systems) was incubated for 20 
min then the revelation solution (Promega, USA) 
was added for 20 min and the reaction was 
stopped with sulfuric acid solution. The 
absorbance at 450 nm was measured using a 
microplate reader (Victor II, Perkin Elmer, 
USA). 
 
Modeling analysis- To design OPG and 
RANKL, sequences were retrieved from the 
Universal Protein resource. Each protein was 
subjected to BLAST searches on the organism 
species (Homo Sapiens) and on the organism 
classification (Mammalia, Vertebrata)(27). 
These sequences were further analyzed using 
multiple sequence alignments to extract the most 
conserved residues (28). The multiple 
alignments were manually adjusted using 
Jalview (29). Human OPG and human RANKL 
models were built using Modeller 9v5 (30) from 
these refined alignments, respectively using 
substructure of DR5 (1D4V) (31) and mouse 
RANKL (1IQA) (32). All resulting models were 
assessed using the Protein Health module of 
Discovery Studio 2.1 (Accelrys Inc, USA). 
Alignment of the A1-domain of vWF on OPG 
has been realized as described below. Structural 
figures were produced with VMD (33) and 
rendered using Pov-Ray 
(http://www.povray.org/). 
 
OPG, RANKL and TRAIL effect on coagulation 
cascade- Plasma of a healthy donor was drawn 
on 0.109 M buffered citrate. OPG, TRAIL and 
RANKL were added to the plasma at 100 ng/ml. 
Primary hemostasis was tested using PFA 100 
automate (Siemens, USA). The Quick time was 
determined using the reagent RecombiPlasTin 
(Instrumentation Laboratory, Spain) on the ACL 
TOP automate (Instrumentation Laboratory). 
The activated partial thromboplastin time (aPTT) 
was tested using TriniCLOT Thrombin Time 
reagent (Trinity Biotech, Ireland) on ACL TOP. 
The thrombin time was tested using Thrombin 
(Siemens) on ACL TOP. The FVIII/C method 
was based on the aPTT. This assay was 
performed using FVIII deficient plasma (Biopep, 
France), an aPTT reagent with kaolin as contact 
phase activator (CK Prest, Diagnostica Stago, 
France) and an ACL TOP coagulometer. 
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Statistical analysis- The mean + SD was 
calculated for all conditions and compared by 
ANOVA, with Bonferroni multiple comparisons 
test as post-hoc test. Differences relative to a 
probability of two-tailed p < 0.05 were 
considered significant. 
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RESULTS 
 
FVIII/vWF inhibits murine and human osteoclast 
differentiation induced by RANKL. The impact 
of the FVIII/vWF complex on osteoclastogenesis 
was first examined using the cellular model 
RAW 264.7. After 5 days of culture with 100 
ng/ml RANKL, RAW 264.7 cells differentiated 
into multinucleated cells. As expected, 50 ng/ml 
OPG inhibited the RANKL-induced 
osteoclastogenesis, by 47 % (p<0.01) (Figure 
1A). Surprisingly, 2 U/ml of FVIII/vWF 
complex inhibited RANKL-induced 
osteoclastogenesis by 42 % (p<0.01), whereas 1 
U/ml of FVIII/vWF complex had no effect on 
RANKL-induced osteoclastogenesis (Figure 
1A). Furthermore, when 2 U/ml of FVIII/vWF 
complex was added to the culture medium in the 
presence of OPG, the inhibition of 
osteoclastogenesis was significantly stronger 
than that observed with OPG alone. Indeed, the 
inhibition of RANKL-induced 
osteoclastogenesis reached 65 % in the presence 
of a mixture OPG, FVIII/vWF complex 
compared to 47 % with OPG alone (p<0.05). 
The recombinant FVIII alone had no effect on 
RANKL-induced osteoclastogenesis of RAW 
264.7 cells (data not shown). 
To ascertain the effect of FVIII/vWF 
complex on osteoclastogenesis, we next 
generated osteoclasts from human CD14+ 
purified from total peripheral blood mononuclear 
cells upon M-CSF and RANKL activation (26). 
As shown in Figures 1B and 1C, and similarly to 
RAW 264.7 cells,  1 U/ml of FVIII/vWF 
complex significantly inhibited by 30% the 
RANKL-induced osteoclastogenesis of CD14+ 
cells (p<0.05) (Figure 1C). Furthermore, 1 U/ml 
of FVIII/vWF complex reinforced the OPG 
inhibitory activity on RANKL-induced 
osteoclastogenesis (P>0.05) (Figure 1C). In 
accordance with the RAW 264.7 cells, the 
recombinant FVIII alone had no effect on 
RANKL mediated osteoclastogenesis (data not 
shown).   
 
RANKL binds to FVIII/vWF complex similarly to 
OPG. To explore the molecular mechanism 
underlying the effect of the FVIII/vWF complex 
on RANKL-induced osteoclastogenesis and the 
possible synergistic effect of OPG and 
FVIII/vWF complex, we investigated the 
molecular interactions between RANKL, OPG, 
FVIII/vWF complex, recombinant FVIII and 
vWF by surface plasmon resonance technique. It 
is well admitted that OPG and vWF are 
physically associated in Weibel-Palade bodies of 
endothelial cells and also in the plasma (24,25). 
Thus, we first immobilized vWF, and confirmed 
that the interaction between OPG and vWF 
depends on the biochemical environment (25). In 
fact, the binding of OPG to immobilized-vWF 
occurred only with 20 mM Bis-Tris pH 6.5 and 
not with 10 mM Hepes pH 7.4 (Figure 2A) and 
the dissociation constant obtained was Kd = 3.51 
10-9 M (Figure 2B). Then, we revealed that, in 
the pH 7.4 buffer, FVIII/vWF complex was also 
able to bind to immobilized-OPG whereas 
recombinant FVIII was not (Figure 2C). 
Furthermore, using a single cycle kinetic assay, 
the Kd of OPG for FVIII/vWF complex was 7.19 
10-8 M (Figure 2D). The binding of OPG to the 
FVIII/vWF complex was also confirmed by 
ELISA assay. As shown in Figure 2E, OPG can 
bind, in a dose dependant manner, to the 
FVIII/vWF complex previously coated. Taken 
together, these results revealed that the 
interaction between OPG and the FVIII/vWF 
complex occurred through the vWF. 
To explore the putative mode of ligand-
receptor binding, we modelled the OPG-RANKL 
interaction using constructs obtained from 
crystallographic coordinates of homologous 
proteins TRAIL-DR5 complex as described by 
Cheng et al. (34). We confirmed that OPG-
RANKL binding model is closely related to 
TRAIL-DR5 binding mode (data not shown). 
The data obtained clearly showed that the OPG-
binding domain to A1-domain of vWF is closely 
located and partly overlaps to its binding site to 
RANKL (Figure 2F). Indeed, the interface shape 
consists of two anchoring points on OPG for 
RANKL by amino acids 68, 69, 82 and amino 
acids 88-91, 111 and 116-120 while the contact 
surface is a continuum for A1-domain of vWF to 
OPG (amino acids 62-69, 82-89) (Figure 2G). 
The binding of FVIII/vWF complex to 
immobilized-RANKL was then investigated in 
the pH 7.4 buffer. Surprisingly, FVIII/vWF 
complex was able to bind to immobilized-
RANKL (response of 150 RU) whereas 
recombinant FVIII was not (Figure 3A). 
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However, when using an immobilized-vWF 
sensorchip, no binding was observed whatever 
the biochemical parameters used (20 mM Bis-
Tris pH 6.5 or 10 mM Hepes pH 7.4) (data not 
shown). As for the binding of OPG to the 
FVIII/vWF complex, we performed an ELISA 
assay using a coating of FVIII/vWF complex. As 
shown in Figure 3B, RANKL was able to bind to 
FVIII/vWF complex, in a dose dependant 
manner, confirming the results obtained by 
surface plasmon resonance experiments. Thus, 
the present data demonstrated for the first time 
the capacity of FVIII/vWF complex to bind 
RANKL. However, in contrast to OPG for which 
the interaction with this complex is done via the 
vWF, our results suggested that the tri-
dimensional structure of the FVIII/vWF complex 
is mandatory for its interaction with RANKL. To 
further explore the involvement of the 
FVIII/vWF complex in the RANKL/OPG 
interactions, the effect of a pre-incubation of 
OPG (100 ng/ml) and increasing concentrations 
of FVIII/vWF complex for 2 hours was assessed. 
The pre-formed FVIII/vWF complex-OPG 
complex was then injected over the 
immobilized-RANKL (Figure 3C). This 
experiment revealed that the pre-formed 
complex FVIII/vWF/OPG did not prevent the 
binding of OPG to RANKL or the binding of 
FVIII/vWF to RANKL. Furthermore, the 
binding of OPG was higher in the presence of 
FVIII/vWF complex than without this complex. 
These results suggest that FVIII/vWF complex 
by binding to RANKL or OPG induced some 
modifications in the three-dimensional structure 
of OPG, RANKL or FVIII/vWF, resulting in a 
higher affinity between OPG and RANKL, and 
then potentially increasing its biological activity. 
Such hypothesis was supported by the 
synergistic effect of OPG-FVIII/vWF complex 
observed on RAW 264.7 cells (Figure 1A). 
Similarly, Figure 3D showed that FVIII/vWF 
complex was still able to bind RANKL or OPG 
even if RANKL had already been bound to 
immobilized-OPG, demonstrating that these 
three molecules can interact together without 
interfering the binding of one to another (see 
Figures 3c and 3d for schematic explanations). 
The same results were observed using 
immobilized-vWF; indeed a pre-formed complex 
OPG/RANKL was able to bind to immobilized-
vWF in the same way as OPG alone 
(Supplementary data). 
 
TRAIL bound to FVIII without affecting 
TRAIL/OPG interactions. OPG is not only a 
decoy receptor for RANKL, but also acts as 
soluble receptor for TRAIL and thus inhibits its 
pro-apoptotic activity (8,10,11). To determine 
whether or not the FVIII/vWF complex could 
affect the complex OPG/TRAIL, TRAIL has 
been immobilized on a sensorchip and the 
capacity of FVIII/vWF complex to bind to 
TRAIL was analyzed. In contrast to the previous 
experiments with OPG and RANKL, both 
FVIII/vWF complex and recombinant FVIII 
were able to bind to immobilized-TRAIL (Figure 
4A and summarized in Figure 4D). Furthermore, 
as for OPG binding to immobilized-vWF, only 
specific biochemical conditions of 20 mM Bis-
Tris pH 6.5 allowed the binding of TRAIL to 
immobilized-vWF (no binding with 10 mM 
Hepes pH 7.4) (data not shown). We confirmed 
that TRAIL bound to immobilized-OPG and 
showed that the complex formed by TRAIL and 
recombinant FVIII was still able to bind 
similarly to OPG (Figure 4B). To further explore 
the involvement of the FVIII/vWF complex in 
the OPG/TRAIL interactions, the effect of a pre-
incubation of OPG and increasing concentrations 
of FVIII/vWF has been investigated. Whatever 
the concentration of FVIII/vWF complex used to 
form a complex with OPG, all these 
combinations completely inhibited the binding of 
OPG to TRAIL (Figure 4C and summarized in 
Figure 4D). These results suggested that the 
binding domains of OPG to vWF and TRAIL is 
very closed and one molecule bound to OPG can 
then block the binding sites of the second. 
To investigate the relevance of this 
inhibition in a biological experiment, we 
performed viability assay on the human 
osteosarcoma cell line MG63 sensitive to 
TRAIL-induced apoptosis. As shown in Figure 
5A, the ability of TRAIL to induce MG63 cell 
death (~75%, p<0.01) was prevented by addition 
of OPG. In contrast, when 1 U/ml of FVIII/vWF 
complex was added to the culture medium OPG 
was not able to prevent the capacity of TRAIL to 
induce MG63 cell death (~60%, p<0.05). 
Furthermore, the apoptotic effect of TRAIL was 
confirmed even in the presence of FVIII/vWF 
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complex and OPG. Nucleus fragmentation was 
observed in MG63 (Figure 5B). In the same 
manner of 50 ng/ml of TRAIL, the combination 
TRAIL + FVIII/vWF complex + OPG induced 
nucleus fragmentation, as the cells exhibited a 
characteristic kidney-like form with condensed 
chromatin clumps compared with control cells. 
Moreover, TRAIL induced a significant increase 
of caspase-3 activity in MG63 cells (p<0.01) 
(Figure 5C) which was significantly reduced in 
the presence of OPG. But the caspase-3 activity 
was not decreased by OPG when FVIII/vWF 
complex was added (p<0.05). The same results 
of viability, Hoechst staining and caspase-3 
activation, were obtained using other cell lines 
sensitive to TRAIL-induced apoptosis such as 
the human osteosarcoma cell line SaOS2 and the 
human Ewing’s sarcoma cell line TC71 (data not 
shown) 
Thus, these data revealed that the 
inhibitory effect of OPG on TRAIL-induced 
apoptosis can be reversed by FVIII/vWF 
complex and then evidenced the role of 
FVIII/vWF complex in the control of cell death. 
 
 
Recombinant human OPG, RANKL and TRAIL 
do not affect the coagulation cascade. Due to the 
different interactions evidenced in our study 
between OPG, RANKL, TRAIL and FVIII/vWF 
complex, we evaluated the potential implications 
of these 3 molecules on the coagulation cascade. 
We demonstrated that 100 ng/ml of OPG, 
RANKL and TRAIL have no effect on the 
following assays: primary hemostasis, Quick 
time, activated partial thromboplastin time 
(aPTT), thrombin time, FVIII/C method based 
on the aPTT (data not shown). 
 
DISCUSSION 
 
Factor VIII (FVIII) associated with the 
von Willebrand factor (vWF) is a key 
protagonist of the coagulation process as 
evidenced in patients suffering from hemophilia 
A. Recent papers revealed the physical 
interaction between vWF and osteoprotegerin 
(OPG) (24,25), a powerful inhibitor of 
osteoclastogenesis and therefore of bone 
resorption (7). Although severe hemophilia 
patients have also joint diseases, to our 
knowledge there is no evidence of the effect of 
FVIII/vWF complex on bone cells and especially 
on osteoclasts. The present work demonstrates 
that FVIII/vWF complex binds to OPG and 
RANKL, and thus indirectly participates to bone 
biology. This paper is thus the first evidence that 
FVIII/vWF complex inhibits RANKL-induced 
osteoclastogenesis. Furthermore, in a second part 
of the manuscript, we also demonstrated for the 
first time that the FVIII/vWF complex abolishes 
the inhibitory effect of OPG on TRAIL-induced 
apoptosis, suggesting a potential function of 
FVIII/vWF complex in cancer development 
(Figure 6). 
In two different models, FVIII/vWF 
complex regulates osteoclastogenesis by 
inhibiting the pro-osteoclastic activity of 
RANKL. Two different effects can be involved 
in this inhibition: the first way of inhibition 
occurs through a physical interaction between 
FVIII/vWF complex and RANKL, leading to an 
inactivation of RANKL; the second potential 
effect is a synergic effect of the FVIII/vWF 
complex with OPG. In fact, both molecules 
inhibit RANKL-induced osteoclastogenesis by 
themselves, but their association in the culture 
medium increased this inhibitory effect. 
However, different mechanisms could be 
proposed. OPG could bind to the FVIII/vWF 
complex through the vWF, and this complex 
could increase the affinity of OPG to RANKL; 
or the complex FVIII/vWF could bind to both 
RANKL and OPG, leading to a stronger 
inhibition of RANKL activity. 
These interactions between FVIII/vWF 
complex, OPG and RANKL point out their 
potential involvement in bone and vascular 
system (7). Indeed, the hallmark of severe 
hemophilia is repeated bleedings into joints and 
muscles resulting in a severe and painful 
inflammation of synovitis named hemophilic 
synovitis (35,36). However, the exact 
mechanism related to blood-induced joint 
disease is not precisely known even if some 
mechanisms are now settled. The processes that 
occur at early stages of blood-induced joint 
disease associated infiltration of inflammatory 
cells releasing high amounts of inflammatory 
cytokines, enzymes (36), proteins such as 
hemoglobin, an increase of intra-articular 
pressure and synovial proliferation. The later 
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stages are characterized by a promotion of 
angiogenesis, cartilage cell apoptosis and 
subchondral bone destruction. Thus, hemophilic 
arthropathy shares several biological features 
with rheumatoid arthritis (37). Numerous studies 
in rheumatoid arthritis models have produced 
evidences for a causal role of excessive RANKL 
activity in associated-bone loss (38). Indeed, 
RANKL levels were concomitantly increased in 
inflamed joint leading to an increase in the 
RANKL/OPG ratio which appears positively 
correlated with bone destruction and osteoclast 
activity (39). The present data evidenced for the 
first time that FVIII/vWF complex inhibits 
RANKL-induced osteoclastogenesis. Moreover 
FVIII/vWF complex did not abolish OPG 
activity on osteoclastogenesis but reinforced its 
activity in murine and human models. In this 
context, hemophilic arthritis may be associated 
with intra-articular inflammatory process 
concomitantly with an increased 
osteoclastogenesis due to a deficiency of 
FVIII/vWF complex. 
OPG/RANK/RANKL triad constitutes a 
molecular bridge spanning bone metabolism, 
vascular biology and immunity (7). The first 
evidence linking the OPG/RANK/RANKL 
system to the vessel biology has been provided 
by the vascular phenotype of OPG deficient mice 
(40). Indeed, OPG-deficient mice exhibited 
medial calcification of the aorta and renal 
arteries and not of smaller vessels, suggesting 
that OPG and its molecular partners may play a 
role in the long term observed association 
between osteoporosis and vascular calcification 
(40). OPG physically associated with the vWF is 
localized in the Weibel-Palade bodies of 
endothelial cells and is rapidly secreted in 
response to inflammatory stimuli (24). More 
recently, in a case-control study, Bilora et al. 
assessed the presence of atherosclerosis in 50 
patients suffering from hemophilia and in 50 
age-matched control individuals (41). Their 
results suggest that hemophilia could protect 
against asymptomatic atherosclerosis. Overall, 
these observations strongly support that the 
OPG/RANK/RANKL and FVIII/vWF systems 
constitute a molecular cascade essential in the 
development of atherosclerotic lesions. 
Furthermore, our present work gives biological 
direct relationship between FVIII/vWF system 
and osteoclastic cells strengthening the interests 
of prophylaxis in young patients suffering from 
severe hemophilia. Even if prophylaxis seems to 
be the best therapeutic option for severe 
hemophilia A in order to prevent joint damages 
(42,43) in evidence based medicine, these results 
are giving a basic explanation for the effect of 
prophylaxis in joint damage and subchondral 
bone erosion prevention. 
The second important result reported in 
our study is the control of cell apoptosis by the 
FVIII/vWF complex. We observed in vitro that 
OPG did not inhibit TRAIL-induced cell 
apoptosis when FVIII/vWF complex was present 
in the culture medium. Physical interactions 
between FVIII/vWF complex, OPG and TRAIL 
were confirmed by surface plasmon resonance 
experiments. We showed that FVIII/vWF 
complex was able to bind to TRAIL, and then 
we demonstrated that, when associated to OPG, 
FVIII/vWF complex prevented the binding 
TRAIL/OPG, correlating the in vitro apoptosis 
experiment. To our knowledge, the functional 
relationship between Factor VIII and/or vWF 
and apoptosis has never been investigated. 
TRAIL is a cytotoxic ligand which binds to type 
I transmembrane receptors (DR4 and DR5) 
possessing death domains and which ultimately 
activates caspase cascade inducing cell death 
(44). TRAIL has also two decoy receptors 
(DcR1, DcR2) which lack functional death 
domain and explain in part the absence of 
massive apoptosis in cells that express functional 
membrane receptor (45). However, normal and 
cancer cells lacking these decoy receptors can 
escape to cell death through the expression of 
OPG which is able to block TRAIL transduction 
signaling (8). It is well established that the 
coagulation cascade contributes to cancer 
development (46) and a clear correlation 
between thrombosis and cancer progression has 
been established. Indeed, tissue factor is 
upregulated on both tumor and host cells in 
cancer patients and initiates protease-activated 
receptor (PAR)-mediated cell signaling that 
leads to the production of soluble cytokines and 
angiogenic growth factors (47). More recently, 
Noé et al. demonstrated that platelets support 
tumor vascular homeostasis by regulating the 
stability of tumor vessels (48). Thus, tumor 
development appears as equilibrium between cell 
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proliferation and cell death actively controlled 
by blood vessels and coagulation cascade. By 
reversing the inhibitory effect of OPG on 
TRAIL-induced apoptosis, FVIII/vWF may 
control tumor growth. Hemophilia A has been 
recently reported after tumor resection in patient 
suffering from glioblastoma (49) and it has been 
suggested that cancer cells could produce factor 
VIII-like tumor antigens. Such hypothesis has 
been also strengthened by Franchini et al., who 
reviewed recently the acquired factor VIII 
inhibitors in oncohematology (50). If the origin 
of such nonclassical antibodies against FVIII is 
not yet defined, these autoantibodies may 
complicate the clinical course of the malignancy 
(51). All these data associated with the present 
work are in favor of a contribution of FVIII/vWF 
complex during cancer disorders. Then the 
interaction between OPG-TRAIL-FVIII/vWF 
complex may be involved in induced cell 
apoptosis (endothelial, cartilage, bone and tumor 
cells) which is essential during angiogenesis 
associated with inflammation and cancer 
disorders.  
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FIGURE LEGENDS 
 
Figure 1: FVIII/vWF complex inhibits RANKL-induced osteoclastogenesis. A. RAW 264.7 
cells were cultured for 5 days in the presence or not of 100 ng/ml hRANKL, 100 ng/ml of OPG, and 1 or 2 
U/ml of FVIII/VWF complex. After May Grünwald / Giemsa (MGG) staining. B. Purified human CD14+ 
monocytes were cultured for 15 days in the presence of 25 ng/ml hM-CSF and 100 ng/ml hRANKL and 1 
U/ml FVIII/vWF. TRAP coloration was performed at the end of the culture period, and (C) Purified 
human CD14+ monocytes were cultured for 15 days in the presence of 25 ng/ml hM-CSF and 100 ng/ml 
hRANKL, with or without 50 ng/ml OPG and 1 U/ml FVIII/vWF. Multinucleated TRAP positive cells 
were counted under a light microscope. (A, C) Results are expressed as number of multinucleated cells 
(more than 3 nuclei) per well: each value represents the mean ± SD. All experiments were performed 
independently 3 times in triplicate. * p<0.05, ** p<0.01.  
 
Figure 2: The interaction between OPG and the FVIII/vWF complex occurred through the vWF. A. 
OPG binds to immobilized-vWF chip in specific biochemical conditions. Binding assays were performed 
using 2 different buffers (pH 7.4 or pH 6.5) as described in experimental procedures section. B. 
Determination of the Kd of OPG for vWF using a Single Cycle Kinetic assay. OPG was injected over 
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immobilized-vWF, in the pH 6.5 buffer, at 25 nM and then ½ dilutions. C. In the pH 7.4 buffer, 
FVIII/vWF complex, but not recombinant Factor VIII, binds to OPG. FVIII/vWF complex (50 U/ml) or 
recombinant Factor VIII (50 U/ml) were injected at a flow rate of 30 µl/min over the immobilized-OPG 
sensorchip for 5 min and the dissociation was monitored for 10 min. D. Determination of the Kd of OPG 
for FVIII/vWF complex, in the pH 7.4 buffer, using a Single Cycle Kinetic assay. FVIII/vWF complex 
was injected over immobilized-OPG starting at 300 nM and then ½ dilutions. E. OPG (500, 100 and 10 
ng/ml) bound to the coated FVIII/vWF complex (1 U/ml) using an ELISA assay. Results are expressed 
using arbitrary units. F. Modeling of the interactions between OPG (green), RANKL (grey) and A1-
domain of vWF (yellow). OPG has the same orientation in the three illustrations. Right illustration is an 
overlay of left and middle illustrations. G. Representation of the binding domains involved in the 
interaction OPG-RANKL and OPG-vWF. OPG-amino acids involved for the binding with RANKL are 
schematized in black, and those involved for the binding with vWF are schematized in yellow. 
 
Figure 3: Complex FVIII/vWF can bind to RANKL and OPG prevents its binding. A. In the 
pH 7.4 buffer, FVIII/vWF complex, but not recombinant Factor VIII, binds to RANKL. FVIII/vWF 
complex (50 U/ml) or recombinant Factor VIII (50 U/ml) were injected at a flow rate of 10 µl/min over 
the immobilized-RANKL sensorchip for 5 min and the dissociation was monitored for 10 min. B. RANKL 
(500, 100 and 10 ng/ml) bound to the coated FVIII/vWF complex (1 U/ml) using an ELISA assay. Results 
are expressed in arbitrary units. C. FVIII/vWF complex increases the binding of OPG to RANKL. OPG 
was incubated with increasing concentrations of FVIII/vWF complex for 2 hours prior to the injection to 
immobilized-RANKL. D. FVIII/vWF complex, OPG and RANKL can form a tripartite complex. 
hRANKL (5 µg/ml) was injected to immobilized-OPG with a flow rate of 20 µl/min, then the FVIII/vWF 
complex was injected. Schematic explanations are represented in Figures 3c and 3d. 
 
Figure 4: TRAIL binds to FVIII without affecting TRAIL/OPG interactions. A. Recombinant 
Factor VIII and FVIII/vWF complex bind to immobilized-TRAIL. Recombinant Factor VIII (50 U/ml) or 
FVIII/vWF complex (50 U/ml) were injected at a flow rate of 30 µl/min over the immobilized-TRAIL for 
2 min association. B. Recombinant Factor VIII bound to TRAIL does not interfere the binding of TRAIL 
to immobilized-OPG. 50 U/ml of recombinant Factor VIII was preincubated with TRAIL for 2 hours at 
room temperature. The complex formed was then injected to immobilized-OPG. C. FVIII/vWF complex 
inhibits the binding of OPG to TRAIL. FVIII/vWF complex was incubated with OPG for 2 hours at room 
temperature; the new complex formed was then injected at a flow rate of 30 µl/min for 2 min over 
immobilized-TRAIL. D. Schematic representation of plasmon resonance experiments a, b, and c 
summarized respectively Figure 4A, 4B and 4C.  
 
Figure 5: FVIII/vWF complex blocks the inhibitory effect of OPG on TRAIL-induced 
apoptosis on MG63 cells. A. Osteosarcoma cell line MG63 was cultured with 100 ng/ml TRAIL +/- 100 
ng/ml OPG +/- 1 U/ml of FVIII/vWF complex. After 72 hours of culture, cell viability was determined by 
XTT assay. Results were expressed as percentage of control. Experiments were performed at least three 
times (* p<0.05). B. Nuclear morphological changes induced by TRAIL, OPG and FVIII/vWF complex 
were analyzed by Hoechst staining on MG63 cells. C. Caspase-3 activity was assessed on MG63 cells 
after 16 hours of treatment with TRAIL, OPG and FVIII/vWF complex (* p<0.05, ** p<0.01). 
 
Figure 6: Schematic representation describing the involvement of FVIII/vWF complex in 
coagulation cascade, bone and cancer biology. FVIII/vWF complex is one of the main complex 
involved in coagulation: FVIII is released from vWF by the action of thrombin and becomes a co-factor 
for Factor IX to stimulate coagulation cascade, while vWF is essential in platelet activation. FVIII/vWF 
complex plays also a major role in other biological processes. Indeed, this complex inhibits RANKL-
induced osteoclastogenesis, by binding to RANKL and also by increasing the anti-osteoclastic activity of 
OPG. Furthermore, FVIII/vWF complex may be involved in cell apoptosis (endothelial, bone and cancer 
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cells): through its binding to OPG, the FVIII/vWF complex inhibits the OPG protective effect on TRAIL-
induced apoptosis which occurs in inflammation and cancer disorders. 
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